<DOC>
	<DOCNO>NCT00337090</DOCNO>
	<brief_summary>The study examine dose YM178 best term efficacy , safety tolerability compare placebo compare tolterodine , market product .</brief_summary>
	<brief_title>A Study YM178 Patients With Symptomatic Overactive Bladder ( DRAGON )</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Mirabegron</mesh_term>
	<criteria>Patients 18 year suffer overactive bladder ( OAB ) 3 month Pregnant breastfeed woman Any medical condition need comedication interfere drug investigation ( YM178 ) comparator ( tolterodine )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Over Active Bladder</keyword>
	<keyword>Urinary incontinence</keyword>
	<keyword>YM178</keyword>
	<keyword>Symptomatic Over Active Bladder</keyword>
</DOC>